大槻 マミ太郎 おおつき まみたろう 先生

来歴等

略歴

1986年 東京大学 医学部医学科 卒業
1986年 東京大学 医学部皮膚科 入局
1990年 米国ニューヨーク大学医療センター 留学
1994年 東京大学 医学部皮膚科 講師
1998年 自治医科大学 皮膚科 助教授
2004年 自治医科大学 皮膚科 教授
2019年 自治医科大学 副学長

論文

• 1. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. J Dermatol. 2020 Oct 25. doi: 10.1111/1346-8138.15655. Epub ahead of print. PMID: 33099791.

  Fujita H, Ohtsuki M, Morita A, Nagao R, Seko N, Matsumoto K, Tani Y, Terui T.

• 2. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur J Dermatol. 2020 Oct 1;30(5):609-611. doi: 10.1684/ejd.2020.3860. PMID: 32972909.

  Kamiya K, Yamauchi H, Ohtsuki M.

• 3. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial. J Dermatol. 2021 Jan;48(1):80-84. doi: 10.1111/1346-8138.15596. Epub 2020 Sep 10. PMID: 32909643.

  Imafuku S, Nemoto O, Okubo Y, Komine M, Schafer P, Petric R, Ohtsuki M.

• 4. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020 May;47(5):452-457. doi: 10.1111/1346-8138.15278. Epub 2020 Mar 15. PMID: 32173900; PMCID: PMC7318330.

  Morita A, Tani Y, Matsumoto K, Yamaguchi M, Teshima R, Ohtsuki M.

• 5. Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: Mamitaro Ohtsuki. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020 Mar;47(3):201-222. doi: 10.1111/1346-8138.15196. Epub 2020 Jan 8. PMID: 31916326.

  Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, Komine M, Etoh T, Igarashi A, Torii H, Abe M, Nakagawa H, Watanabe A, Yotsuyanagi H, Ohtsuki M.

• 6. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2020 Jul;183(1):39-51. doi: 10.1111/bjd.18565. Epub 2019 Nov 28. PMID: 31564057; PMCID: PMC7384164.

  Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M.

• 7. dsRNA induces IL-33 promoter activity through TLR3-EGFR-IRF3 pathway in normal human epidermal keratinocytes. J Dermatol Sci. 2019 Dec;96(3):178-180. doi: 10.1016/j.jdermsci.2019.11.002. Epub 2019 Nov 19. PMID: 31810599.

  Jin M, Komine M, Tsuda H, Oshio T, Ohtsuki M.

• 8. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020 Jan;47(1):33-40. doi: 10.1111/1346-8138.15146. Epub 2019 Nov 6. PMID: 31696543.

  Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M.

• 9. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 Sep 5;20(18):4347. doi: 10.3390/ijms20184347. PMID: 31491865; PMCID: PMC6769762.

  Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M.

• 10. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. PMID: 31218661; PMCID: PMC7064936.

  Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqu?s M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Tha?i D.

• 11. Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine. J Dermatol. 2019 Nov;46(11):e442-e443. doi: 10.1111/1346-8138.15007. Epub 2019 Jul 4. PMID: 31271448.

  Yoneyama S, Kamiya K, Kishimoto M, Komine M, Ohtsuki M.

• 12. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. J Dermatol. 2019 Aug;46(8):686-694. doi: 10.1111/1346-8138.14941. Epub 2019 Jun 25. PMID: 31237727; PMCID: PMC6771602.

  Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, Kitamura S, Valdes J, Igarashi A.

• 13. Extension Study Japanese Subgroup. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. J Dermatol. 2019 Mar;46(3):186-192. doi: 10.1111/1346-8138.14761. Epub 2019 Jan 23. PMID: 30672623; PMCID: PMC6590222.

  Okubo Y, Ohtsuki M, Morita A, Yamaguchi M, Shima T, Tani Y, Nakagawa H.

• 14. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution. J Dermatol. 2019 Mar;46(3):199-205. doi: 10.1111/1346-8138.14782. Epub 2019 Jan 23. PMID: 30672612.

  Kamiya K, Karakawa M, Komine M, Kishimoto M, Sugai J, Ohtsuki M.

• 15. Late-onset psoriatic arthritis in Japanese patients. J Dermatol. 2019 Feb;46(2):169-170. doi: 10.1111/1346-8138.14752. Epub 2019 Jan 4. PMID: 30614050.

  Yamamoto T, Ohtsuki M, Sano S, Morita A, Igarashi A, Okuyama R, Kawada A.

• 16. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018 Nov;45(11):1345-1348. doi: 10.1111/1346-8138.14617. Epub 2018 Aug 31. PMID: 30168880.

  Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.

• 17. working group of the epidemiological survey in the Japanese Society for Psoriasis Research. Switching biologics in the treatment of psoriatic arthritis in Japan. J Dermatol. 2019 Mar;46(3):e113-e114. doi: 10.1111/1346-8138.14622. Epub 2018 Aug 29. PMID: 30156313.

  Yamamoto T, Ohtsuki M, Sano S, Morita A, Igarashi A, Okuyama R, Kawada A.

• 18. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. PMID: 30097359.

  Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

• 19. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. J Dermatol. 2018 Aug;45(8):936-942. doi: 10.1111/1346-8138.14501. Epub 2018 Jun 21. PMID: 29927498; PMCID: PMC6099320.

  Ohtsuki M, Morimoto H, Nakagawa H.

• 20. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018 Sep;45(9):1053-1062. doi: 10.1111/1346-8138.14504. Epub 2018 Jun 15. PMID: 29905383; PMCID: PMC6175099.

  Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.

• 21. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast. Eur J Dermatol. 2018 Jun 1;28(3):413-414. doi: 10.1684/ejd.2018.3280. PMID: 29619999.

  Waki Y, Kamiya K, Komine M, Maekawa T, Murata S, Ishii N, Hashimoto T, Ohtsuki M.

• 22. Juvenile-onset psoriatic arthritis: a survey by the Japanese Society for Psoriasis Research. Eur J Dermatol. 2018 Jun 1;28(3):419-421. doi: 10.1684/ejd.2018.3286. PMID: 29619985.

  Yamamoto T, Ohtsuki M, Sano S, Igarashi A, Morita A, Okuyama R, Wada M, Katoh N, Kawada A.

• 23. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018 Mar;178(3):674-681. doi: 10.1111/bjd.16050. Epub 2018 Feb 23. PMID: 28991370.

  Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.

• 24. Generalized pustular psoriasis in a 92-year-old man with a homozygous nonsense mutation in IL36RN. J Dermatol. 2018 Mar;45(3):326-328. doi: 10.1111/1346-8138.14132. Epub 2017 Dec 7. PMID: 29215143.

  Ueda Y, Komine M, Kamiya K, Tsuda H, Maekawa T, Murata S, Ohtsuki M.

• 25. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018 Apr;32(4):606-614. doi: 10.1111/jdv.14630. Epub 2017 Nov 6. PMID: 29034518; PMCID: PMC5900866.

  Okubo Y, Tsuruta D, Tang AC, Inoue S, Torisu-Itakura H, Hanada T, Ohtsuki M.

• 26. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol. 2017 Oct;44(10):1105-1111. doi: 10.1111/1346-8138.13911. Epub 2017 May 23. PMID: 28543617; PMCID: PMC5655923.

  Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H, Fujishige A, Yamaguchi M, Teshima R, Tani Y, Nakagawa H.

• 27. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. PMID: 28391657; PMCID: PMC5573969.

  Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.

• 28. Identification of the promoter region of human IL-33 responsive to induction by IFNγ. J Dermatol Sci. 2017 Feb;85(2):137-140. doi: 10.1016/j.jdermsci.2016.11.002. Epub 2016 Nov 9. PMID: 27955843.

  Tsuda H, Komine M, Tominaga SI, Ohtsuki M.

• 29. Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci. 2017 Feb;85(2):106-114. doi: 10.1016/j.jdermsci.2016.10.008. Epub 2016 Oct 17. PMID: 27839630.

  Oshio T, Komine M, Tsuda H, Tominaga SI, Saito H, Nakae S, Ohtsuki M.

• 30. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. PMID: 27299809.

  Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group.

• 31. 日本皮膚科学会ガイドライン　乾癬性関節炎診療ガイドライン2019

  Author：朝比奈 昭彦(東京慈恵会医科大学 皮膚科), 梅澤 慶紀, 大槻 マミ太郎, 奥山 隆平, 加藤 則人, 金子 敦史, 亀田 秀人, 岸本 暢将, 佐野 栄紀, 多田 弥生, 照井 正, 中川 秀己, 長谷川 友紀, 福田 国彦, 森田 明理, 山本 俊幸, 井汲 菜摘, 岡野 匡志, 岡本 奈美, 高井 千夏, 福田 健志, 村島 温子, 森 雅亮, 日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会, 厚生労働科学研究費補助金難治性疾患等政策研究事業乾癬性関節炎研究班　Source：日本皮膚科学会雑誌(0021-499X)129巻13号 Page2675-2733(2019.12)　論文種類：解説/診療ガイドライン

• 32. 日本皮膚科学会マニュアル　乾癬における生物学的製剤の使用ガイダンス(2019年版)

  Author：大槻 マミ太郎(自治医科大学), 佐伯 秀久, 照井 正, 森田 明理, 佐野 栄紀, 今福 信一, 朝比奈 昭彦, 小宮根 真弓, 江藤 隆史, 鳥居 秀嗣, 安部 正敏, 五十嵐 敦之, 中川 秀己, 渡辺 彰, 四柳 宏, 日本皮膚科学会乾癬生物学的製剤検討委員会　Source：日本皮膚科学会雑誌(0021-499X)129巻9号 Page1845-1864(2019.08)　論文種類：解説/診療ガイドライン

• 33. アトピー性皮膚炎治療におけるステロイド外用薬およびタクロリムス軟膏の使用実態調査

  Author：大槻 マミ太郎(自治医科大学 皮膚科), 五十嵐 敦之, 勝沼 俊雄, 藤澤 隆夫　Source：日本皮膚免疫アレルギー学会雑誌(2433-7846)1巻3号 Page163-176(2018.07)　論文種類：原著論文

著書

• 1. 皮膚科で使うMTXの完全マニュアル Visual Dermatology 18巻1号／学研メディカル秀潤社／2019年／（編集：大槻 マミ太郎）

• 2. ヴィジュアルでみるステロイド外用薬の使い方ガイド: 副作用の正確な知識から役に立つ裏ワザまで／学研メディカル秀潤社／2015年／（編集：江藤隆史、大槻マミ太郎）

• 3. ここまでわかった 乾癬の病態と治療（皮膚科臨床アセット）／中山書店／2012年／（責任編集：大槻マミ太郎、総編集：古江増隆）

その他

• 【テレビ出演】2017年5月18 日放送　NHK：日本人のおなまえっ「太郎」特集